Drug intelligence / Profile preview

ABX-05

Development stage: Preclinical
Lead developer: Centauri Therapeutics
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides

Overview

ABX-05 is a constrained peptide conjugate being developed by Centauri Therapeutics for the treatment of acute *Escherichia coli* (E. coli) infections. It is part of Centauri's Alphamer platform, which utilizes chemically synthesized molecules to redirect naturally occurring antibodies to the surface of pathogens, thereby triggering an immune response to clear the infection. The asset is currently in the lead optimization stage of development.

Targets

n-AGA (Naturally occurring anti-glycan antibody)

Beyond the preview

Go deeper on ABX-05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABX-05.

Explore the full profile